The notices it replaced
- Reissues: RFA-MH-18-703 Early Stage Testing of Pharmacologic or Device -based Interventions for the Treatment of Mental Health Disorders (R33- Clinical Trial Required)
- 2 steps back: RFA-MH-17-602 Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33)
Replaced by PAR-25-183.
Who won it before
1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1 in first-year total cost, median $1.
Most frequent study sections
- Special Emphasis Panel[ZMH1 ERB-L (05)]1
Most frequent institutions
- UNIVERSITY OF CALIFORNIA, SAN DIEGO1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2022 | Target Engagement and Clinical Symptom Change with a FAAH Inhibitor for Posttraumatic Stress Disorder1R33MH126149-01A1 · under RFA-MH-18-703 | PAULUS, MARTIN P.RISBROUGH, VICTORIA BSTEIN, MURRAY B. | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $1 | ZMH1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.